Company Filing History:
Years Active: 2025
Title: Matthew Chiocco: Innovator in Gene Therapy
Introduction
Matthew Chiocco is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of gene therapy, particularly in the development of non-viral DNA vectors. His work focuses on innovative solutions for expressing phenylalanine hydroxylase (PAH) therapeutics, which are crucial for treating genetic disorders such as Phenylketonuria (PKU).
Latest Patents
Matthew Chiocco holds 1 patent for his invention titled "Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeutics." This patent describes ceDNA vectors that have a linear and continuous structure designed for the delivery and expression of a transgene. The ceDNA vectors include an expression cassette flanked by two ITR sequences, encoding the PAH protein. Additionally, some ceDNA vectors incorporate cis-regulatory elements, including regulatory switches. The patent also outlines methods and cell lines for reliable gene expression of PAH protein in vitro, ex vivo, and in vivo using these ceDNA vectors.
Career Highlights
Matthew Chiocco is currently associated with Generation Bio Co., where he continues to advance his research in gene therapy. His innovative approach to developing ceDNA vectors has the potential to revolutionize treatment methods for diseases related to PAH deficiency.
Collaborations
Matthew collaborates with notable colleagues, including Douglas Anthony Kerr and Phillip Samayoa, who contribute to his research endeavors and the advancement of gene therapy technologies.
Conclusion
Matthew Chiocco's work in developing non-viral DNA vectors represents a significant advancement in gene therapy, offering new hope for patients with genetic disorders. His contributions to the field are paving the way for innovative treatment options.